Your browser doesn't support javascript.
loading
Polypharmacy, comorbidity and frailty: a complex interplay in older patients at the emergency department.
van Dam, Carmen S; Labuschagne, Helena A; van Keulen, Kris; Kramers, Cornelis; Kleipool, Emma E; Hoogendijk, Emiel O; Knol, Wilma; Nanayakkara, Prabath W B; Muller, Majon; Trappenburg, Marijke C; Peters, Mike J L.
Afiliação
  • van Dam CS; Department of Internal Medicine and Geriatrics, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands. c.vandam@amsterdamumc.nl.
  • Labuschagne HA; Department of Internal Medicine and Geriatrics, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
  • van Keulen K; Department of Pharmacy, Amstelland Hospital, Amstelveen, the Netherlands.
  • Kramers C; Department of Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Kleipool EE; Department of Internal Medicine and Geriatrics, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
  • Hoogendijk EO; Department of Epidemiology and Data Science, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
  • Knol W; Department of Geriatric Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Nanayakkara PWB; Section General and Acute Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
  • Muller M; Department of Internal Medicine and Geriatrics, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
  • Trappenburg MC; Department of Internal Medicine and Geriatrics, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
  • Peters MJL; Department of Pharmacy, Amstelland Hospital, Amstelveen, the Netherlands.
Eur Geriatr Med ; 13(4): 849-857, 2022 08.
Article em En | MEDLINE | ID: mdl-35723840
ABSTRACT

PURPOSE:

Older adults at the emergency department (ED) with polypharmacy, comorbidity, and frailty are at risk of adverse health outcomes. We investigated the association of polypharmacy with adverse health outcomes, in relation to comorbidity and frailty.

METHODS:

This is a prospective cohort study in ED patients ≥ 70 years. Non-polypharmacy was defined as 0-4 medications, polypharmacy 5-9 and excessive polypharmacy ≥ 10. Comorbidity was classified by the Charlson comorbidity index (CCI). Frailty was defined by the Identification of Seniors At Risk-Hospitalized Patients (ISAR-HP) score. The primary outcome was 3-month mortality. Secondary outcomes were readmission to an ED/hospital ward and a self-reported fall < 3 months. The association between polypharmacy, comorbidity and frailty was analyzed by logistic regression.

RESULTS:

881 patients were included. 43% had polypharmacy and 18% had excessive polypharmacy. After 3 months, 9% died, 30% were readmitted, and 21% reported a fall. Compared with non-polypharmacy, the odds ratio (OR) for mortality ranged from 2.62 (95% CI 1.39-4.93) in patients with polypharmacy to 3.92 (95% CI 1.95-7.90) in excessive polypharmacy. The OR weakened after adjustment for comorbidity 1.80 (95% CI 0.92-3.52) and 2.32 (95% CI 1.10-4.90). After adjusting for frailty, the OR weakened to 2.10 (95% CI 1.10-4.00) and OR 2.40 (95% CI 1.15-5.02). No significant association was found for readmission or self-reported fall.

CONCLUSIONS:

Polypharmacy is common in older patients at the ED. Polypharmacy, and especially excessive polypharmacy, is associated with an increased risk of mortality. The observed association is complex given the confounding effect of comorbidity and frailty.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragilidade Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragilidade Idioma: En Ano de publicação: 2022 Tipo de documento: Article